中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents

Research advances in integrated traditional Chinese and Western medicine therapy for liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.09.001
More Information
  • Corresponding author: LIU Ping, liuliver@vip.sina.com(ORCID: 0000-0002-6152-4508)
  • Received Date: 2022-07-25
  • Accepted Date: 2022-08-25
  • Published Date: 2022-09-20
  • The combination of traditional Chinese medicine and Western medicine is an important approach to improve the treatment outcome of liver cirrhosis. Long-term diagnosis and treatment practice and clinical studies of the prevention and treatment of chronic hepatitis B cirrhosis have shown that antiviral drugs targeting the cause of the disease combined with anti-liver fibrosis traditional Chinese medicine can significantly improve the reversal rate of liver fibrosis and cirrhosis, and anti-liver fibrosis therapy can reduce the incidence rates of esophagogastric variceal bleeding and hepatocellular carcinoma in cirrhotic patients and improve the 5-year survival rate of patients with decompensated liver cirrhosis. It is necessary to conduct in-depth studies to clarify the target and mechanism of action of the main effective constituents of compound traditional Chinese medicine, strengthen the research on drug quality control standards, and obtain more high-quality evidence for clinical efficacy, so as to effectively promote the development of integrated traditional Chinese and Western medicine therapy for liver cirrhosis.

     

  • loading
  • [1]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [3]
    SHI K, ZHANG Q, HUANG YY, et al. Effects of anti-liver fibrosis treatment on the occurrence of liver cancer in patients with hepatitis B-related liver cirrhosis[J]. Chin J Hepatol, 2021, 29(7): 685-689. DOI: 10.3760/cma.j.cn501113-20200227-00072.

    时克, 张群, 黄云义, 等. 抗肝纤维化治疗对乙型肝炎肝硬化患者发生肝癌的影响[J]. 中华肝脏病杂志, 2021, 29(7): 685-689. DOI: 10.3760/cma.j.cn501113-20200227-00072.
    [4]
    RONG G, CHEN Y, YU Z, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225(6): 1091-1099. DOI: 10.1093/infdis/jiaa266.
    [5]
    MIAO L, YANG WN, DONG XQ, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009.

    苗亮, 杨婉娜, 董晓琴, 等. 安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J]. 中华肝脏病杂志, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009.
    [6]
    GUI HL, ZHAO CQ, WANG Y, et al. Histological outcome of Fuzheng Huayu plus entecavir combination therapy in chronic hepatitis B patients with significant liver fibrosis[J]. J Clin Transl Hepatol, 2020, 8(3): 277-284. DOI: 10.14218/JCTH.2020.00004.
    [7]
    Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention for primary liver cancer (2021 edition)[J]. J Clin Hepatol, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.

    中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.
    [8]
    SHI K, LIU Y, WANG X, et al. Adjuvant Fuzheng Huayu Capsule reduces the incidence of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis[J]. Evid Based Complement Alternat Med, 2020, 2020: 8826091. DOI: 10.1155/2020/8826091.
    [9]
    GE XJ, ZHAO CQ, XU LM. Effect of Fuzheng Huayu capsules on survival rate of patients with liver cirrhosis[J]. Chin J Hepatol, 2017, 25(11): 834-840. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.007.

    戈雪婧, 赵长青, 徐列明. 扶正化瘀胶囊对肝硬化患者生存率的影响[J]. 中华肝脏病杂志, 2017, 25(11): 834-840. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.007.
    [10]
    XIAO DH, GU J, CAI H, et al. A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Hepatol, 2014, 22(8): 594-599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009.

    肖定洪, 顾杰, 蔡虹, 等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]. 中华肝脏病杂志, 2014, 22(8): 594-599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009.
    [11]
    NIU SS, ZHANG Q, HOU YX, et al. Primary preventive effect of anti-fibrosis treatment on esophageal and gastric varices bleeding in patients with cirrhosis: a real-world study[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006.

    牛帅帅, 张群, 侯艺鑫, 等. 抗肝纤维化治疗对肝硬化食管胃静脉曲张出血的一级预防作用[J]. 中西医结合肝病杂志, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1017) PDF downloads(170) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return